CD274 and neoplasm: Impower-131 and Impower-132 trials did not demonstrate a statistically significant difference in the intention-to-treat OS analysis, potentially explained by subsequent second-line treatments, percentage of PD-L1 tumor expression, patient population selection, overperformance of comparators arms, and possible differences across PD-1 and PD-L1 treatments.